RxDoctor Payments Data

Maria Coimbra, MD

Family Medicine · McAllen, TXNPI 1316188725

Payments from drug & device makers

$58,746in general payments, 2019–2025

Across 130 payments — averaging $451.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$52K
  • Astellas Pharma US Inc$5K
  • Novo Nordisk$392
  • AbbVie$320
  • Amgen$238
  • GSK$236
  • plus $875 from 17 others

What the payments were for

  • Consulting fees$3,42348%
  • Travel & lodging$1,25717%
  • Food & beverage$2,50435%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$58,746 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$44,095
Medicare patients
86
Services billed
1,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$210,740
JanuviaSitagliptin Phosphate44$66,670
EliquisApixaban51$60,371
JardianceEmpagliflozin36$48,846
JanumetSitagliptin Phos/Metformin Hcl29$37,827
TrulicityDulaglutide21$35,228
MounjaroTirzepatide27$33,778
Tresiba Flextouch U-200Insulin Degludec30$27,697
RybelsusSemaglutide11$23,000
FarxigaDapagliflozin Propanediol17$17,983
LinzessLinaclotide12$16,075
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,876
XareltoRivaroxaban20$14,449
Desloratadine237$13,988
MyrbetriqMirabegron15$9,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$392$233,740184 claims
Lilly USA, LLCTrulicity, Mounjaro$179$69,00748 claims
PfizerEliquis$53$60,37151 claims
Boehringer IngelheimJardiance$27$48,84636 claims
AstraZenecaFarxiga$99$17,98317 claims
AbbVieLinzess$320$16,07512 claims
GSKTrelegy Ellipta$236$15,87617 claims
Johnson & JohnsonXarelto$13$14,44920 claims
Astellas Pharma US IncMyrbetriq$5,124$9,72915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →